17:03 , Jan 4, 2019 |  BC Week In Review  |  Financial News

China's Antengene raises $120M series B round

Antengene Corp. (Shanghai, China) completed a $120 million series B round on Jan. 2 to fund development of its two lead cancer compounds, selinexor and ATG-008. Boyu Capital and FountainVest led the round, with participation...
21:56 , Jan 2, 2019 |  BC Extra  |  Financial News

China's Antengene raises $120M series B round

Antengene Corp. (Shanghai, China) completed a $120 million series B round to fund development of its two lead cancer compounds, selinexor and ATG-008. Boyu Capital and FountainVest led the round, with participation by Celgene Corp....
18:21 , May 25, 2018 |  BC Week In Review  |  Company News

Antengene adds bundle of Karyopharm assets to pipeline

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) granted cancer company Antengene Corp. (Shanghai, China) exclusive Asian rights to four compounds, significantly building out the Chinese company's clinical pipeline. Antengene will develop and commercialize Karyopharm's selinexor (KPT-330) and eltanexor...
22:16 , May 24, 2018 |  BC Extra  |  Company News

Antengene fills pipeline with Karyopharm deal

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) granted cancer company Antengene Corp. (Shanghai, China) exclusive Asian rights to four compounds, significantly building out the Chinese company's clinical pipeline. Antengene will develop and commercialize Karyopharm's selinexor (KPT-330) and eltanexor...
18:41 , Sep 1, 2017 |  BioCentury  |  Finance

Armo's China network

Chinese investors in Armo BioSciences Inc. 's $67 million series C-1 round could help the Redwood City, Calif., company establish local partnerships and bring its lead cancer therapy to the China market. Qiming Venture Partners...
17:17 , Aug 18, 2017 |  BioCentury  |  Finance

Ante Antengene

With a track record of bringing drugs to market in China, the founder of Chinese in-licensing play Antengene Corp. convinced Qiming Venture Partners to lead its $21 million series A round. Antengene closed the round...
16:27 , Aug 18, 2017 |  BC Week In Review  |  Financial News

Antengene raises $21M series A

Antengene Corp. (Shanghai, China) raised $21 million on Aug. 16 in a series A round led by Qiming Venture Partners with participation by TF Capital, HG Capital and Tigermed Investment. Antengene has exclusive rights to...
22:34 , Aug 16, 2017 |  BC Extra  |  Financial News

Antengene raises $21M series A

Antengene Corp. (Shanghai, China) raised $21 million in a series A round led by Qiming Venture Partners with participation by TF Capital, HG Capital and Tigermed Investment. Antengene has exclusive rights to ATG-008 (CC-223), an...
00:22 , Jul 7, 2017 |  BC Extra  |  Company News

BeiGene grants Celgene PD-1 rights, acquires China operations

BeiGene Ltd. (NASDAQ:BGNE) granted Celgene Corp. (NASDAQ:CELG) exclusive rights in most of the world to its PD-1 inhibitor BGB-A317 for non-hematological indications and acquired Celgene's commercial operations in China, including local rights to a handful...
20:34 , Apr 21, 2017 |  BC Week In Review  |  Company News

Celgene, Antengene deal

Antengene gained rights in Taiwan and China, including Hong Kong and Macau, to oncology candidate CC-223 from Celgene. Celgene received an undisclosed equity stake in Antengene, and took a board seat. Antengene will be responsible...